If you have previously registered for this event, please login below:

Registration is required to attend this event. Please register now.
First Name*
Last Name*
Job Title*
Street Address *
Street Address Line 2
Zip/Postal Code*
Confirm Email*
You may contact me by email. 
Please enable Cookies in your browser before registering for the webcast.
*Denotes required.
You must have Javascript and Cookies enabled to access this webcast. Click here for Help.
Improving Probability of Success in Drug Development: Opportunities in Early Phase Trials

Event Date: June 13, 2017 11:00 am ET | 15:00 (GMT/UTC)

Groundbreaking innovations in basic science are "pushing" clinical development to be agile and creative, with the intent of translating scientific discoveries into medical benefit more rapidly and convincingly, while reducing failure rates in Late Phase development. Clinical development is shifting from the traditional static Phase I-II-III structure to a more fluid continuum that leverages tools like adaptive designs and drives continuous drug development from Early Phases to Late Phases. Regulators support this shift, as long as sponsors present it persuasively. What does this mean for the future of Early Phase clinical trials?

Topics for discussion:
  • Study design options in Early Phase
  • Using adaptive designs in Early Phase trials
  • Benefits of innovative approaches in Early Phase
  • How Early Phase trials will be conducted in the future
  • Practical considerations in Early Phase trials

Who should attend:
Professionals from pharmaceutical and biotechnology companies involved in early phase trials.

This webinar is intended for pharmaceutical and biotechnology professionals. A valid business email address is required to attend. This webinar is complimentary.

Featured Speakers:

Martin Roessner, MS, Vice President Global Biostatistics, PAREXEL

Ronald Goldwater, MD, Medical Director, PAREXEL Baltimore Early Phase Clinical Unit